All In Biotech

Drug Trial Radar · NCT06468098

A Study of IBI363 in Subjects With Advanced Malignancies

Phase Ib Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of IBI363 Combination Therapy in Subjects With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 556 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

556

Planned (sponsor's estimate)

Start

Jun 15, 2024

Primary completion

Jun 30, 2025

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Jun 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter Phase Ib study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced malignancies patients

Conditions

  • Advanced Malignancies

Interventions

  • IBI363 + chemotherapyDrug

    In this group, patients will receive IBI363 and chemotherapy

  • IBI363 + Investigator's Choice SOCDrug

    In this group, patients will receive IBI363 and Investigator's Choice SOC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Enent (AE)Time frame: Up to 90 days after the last administration
  2. Treatment-Emergent AE (TEAE)Time frame: Up to 90 days after the last administration
  3. Adverse Event of Special Interest (AESI)Time frame: Up to 90 days after the last administration
  4. Serious Adverse Event (SAE)Time frame: Up to 90 days after the last administration
  5. Objective response rate (ORR)Time frame: Through out the study (up to 2 years)
  6. disease control rate (DCR)Time frame: Through out the study (up to 2 years)
  7. time to response (TTR)Time frame: Through out the study (up to 2 years)
  8. duration of response (DoR)Time frame: Through out the study (up to 2 years)
  9. progression-free survival (PFS)Time frame: Through out the study (up to 2 years)
  10. Overall survival (OS)Time frame: Through out the study (an average of 2 years)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospita

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.